Skip to main content
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

Press Releases

<< Back
Printer Friendly Version View printer-friendly version
Seres Therapeutics to Participate in Three Upcoming November Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 8, 2017-- Seres Therapeutics, Inc., (NASDAQ:MCRB) today announced that it will participate in each of the following upcoming healthcare conferences:

  • Stifel 2017 Healthcare Conference: A corporate overview will be presented on Tuesday, November 14 at 5:00 p.m. ET in New York, NY.
  • 29th Annual Piper Jaffray Healthcare Conference: A corporate overview will be presented on Wednesday, November 29 at 10:30 a.m. ET in New York, NY.
  • Evercore ISI Biopharma Catalyst/Deep Dive Conference: Members of the management team will participate in one-on-one meetings on Thursday, November 30 in Boston, MA.

A live audio webcast of each presentation will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc., is a leading microbiome therapeutics platform Company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for multiply recurrent C. difficile infection. Seres’ clinical candidate SER-287 has successfully completed a Phase 1b study in patients with mild-to-moderate Ulcerative Colitis. Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary C. difficile infection. For more information, please visit Follow us on Twitter @SeresTx.

Source: Seres Therapeutics, Inc.

IR or PR Contact:
Seres Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate Communications